Abstract
Accumulating evidence implicates a failure of myelin-reactive immune cells to undergo apoptosis in the pathological events contributing to multiple sclerosis (MS). We have recently demonstrated that members of the inhibitor of apoptosis (IAP) family of antiapoptotic genes are elevated in peripheral blood immune cells (monocytes, T cells) of patients with aggressive forms of MS (secondary progressive) or those with relapsing-remitting MS suffering a disease replase. These findings suggest that the IAPs may be novel diagnostic markers for distinguishing subtypes of MS. Moreover, antisense-mediated knockdown of the IAP family member known as Xlinked IAP (XIAP) reverses paralysis in an animal model of MS suggesting that treatments targeting XIAP, and perhaps other IAPs, may have utility in the treatment of MS.
Current Drug Discovery Technologies
Title: Targeting Apoptosis to Treat Multiple Sclerosis
Volume: 5 Issue: 1
Author(s): George S. Robertson, Andrea L.O. Hebb, Craig S. Moore and Virender Bhan
Affiliation:
Abstract: Accumulating evidence implicates a failure of myelin-reactive immune cells to undergo apoptosis in the pathological events contributing to multiple sclerosis (MS). We have recently demonstrated that members of the inhibitor of apoptosis (IAP) family of antiapoptotic genes are elevated in peripheral blood immune cells (monocytes, T cells) of patients with aggressive forms of MS (secondary progressive) or those with relapsing-remitting MS suffering a disease replase. These findings suggest that the IAPs may be novel diagnostic markers for distinguishing subtypes of MS. Moreover, antisense-mediated knockdown of the IAP family member known as Xlinked IAP (XIAP) reverses paralysis in an animal model of MS suggesting that treatments targeting XIAP, and perhaps other IAPs, may have utility in the treatment of MS.
Export Options
About this article
Cite this article as:
Robertson S. George, Hebb L.O. Andrea, Moore S. Craig and Bhan Virender, Targeting Apoptosis to Treat Multiple Sclerosis, Current Drug Discovery Technologies 2008; 5 (1) . https://dx.doi.org/10.2174/157016308783769432
DOI https://dx.doi.org/10.2174/157016308783769432 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
T-Cell Antigen Receptor Assembly and Cell Surface Expression Is Not Affected by Treatment with T-Cell Antigen Receptor-Alpha Chain Transmembrane Peptide
Protein & Peptide Letters Assessment of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-Beta1 Serum Titers in Relapsing Remitting Multiple Sclerosis Patients Treated with Avonex, Possible Biomarkers for Treatment Response
CNS & Neurological Disorders - Drug Targets Immunotherapy for Conformational Diseases
Current Pharmaceutical Design Immune Stimulatory Strategies for the Prevention and Treatment of Asthma
Current Pharmaceutical Design Advances in Drug Delivery from Nose to Brain: An Overview
Current Drug Therapy Nuclear Factor-κB: A Holy Grail in Cancer Prevention and Therapy
Current Signal Transduction Therapy Sphingosine-1-Phosphate Receptors in the Central Nervous and Immune Systems
Current Drug Targets Gene Therapy and Biologic Therapy with Interleukin?4
Current Gene Therapy Humanized Cobra Venom Factor: Experimental Therapeutics for Targeted Complement Activation and Complement Depletion
Current Pharmaceutical Design Inflammation: Beneficial or Detrimental After Spinal Cord Injury?
Recent Patents on CNS Drug Discovery (Discontinued) The Gut Mucosa as a Site for Induction of Regulatory T-Cells
Current Pharmaceutical Design Role of Cytokines in Neurological Disorders
Current Medicinal Chemistry Immunological Approaches to Prevent Neuronal Apoptosis During Neuroinflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Induced Stem Cells as a Novel Multiple Sclerosis Therapy
Current Stem Cell Research & Therapy Chronic Inflammatory Diseases: Progress and Prospect with Herbal Medicine
Current Pharmaceutical Design Endogenous Retroelements in Cellular Senescence and Related Pathogenic Processes: Promising Drug Targets in Age-Related Diseases
Current Drug Targets Tryptophan Catabolites and Their Impact on Multiple Sclerosis Progression
Current Pharmaceutical Design Organotypic Cultures as Tool to Test Long-Term Effects of Chemicals on the Nervous System
Current Medicinal Chemistry Stroke and Neuroinflamation: Role of Sexual Hormones
Current Pharmaceutical Design Chemistry and Applications of 4-Hydroxyquinolin-2-one and Quinoline-2,4-dionebased Compounds
Current Organic Chemistry